

*3fu*

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

21 July 2005  
(Date of Deposit)

Kirk Baumeister  
(Name of applicant, assignee, or Registered Representative)

*Kirk Baumeister*  
(Signature)

21 July 2005  
(Date of Signature)

Docket No. CEN5063 USA CIP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Glen A. Evans                      21 July 2005  
Serial No. : 10/705,217                      Art Unit: Unknown  
Filed : 07 November 2003                      Examiner: Unknown  
For : Enhanced Variants of Erythropoietin and  
Methods of Use

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material

to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of the U.S. patent listed on the attached Form PTO-1449 is not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30,

CEN5063 USA CIP

2003 (see USPTO waiver of requirement under 37 CFR 1.98  
(a)(2)(i)).

☒ There are no listed references which are not in the English language.


☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN5063 USA CIP/KB.

Respectfully submitted,



**Kirk Baumeister**

Reg. No. 33,833

Attorney for Applicants

**Johnson & Johnson**

One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(610)240-8465

DATED: 21 July 2005



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

<i>Application Number</i>	10/705,217
<i>Filing Date</i>	07 November 2003
<i>First Named Inventor</i>	Glen A. Evans
<i>Group Art Unit</i>	Unknown
<i>Examiner Name</i>	Unknown
<i>Attorney Docket Number</i>	CEN5063 USA CIP

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
		6,077,939		Wei, et al.	06/20/2000	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Dale A. Cumming, "Glycosylation of recombinant protein therapeutics: control and functional implications," <i>Glycobiology</i> , 1(2): 115-130 (1991).	
		Lowy, et al., "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," <i>Nature</i> , 185: 102-103 (1960).	
		Goodman, et al., "Chapter 20: Peptidomimetics for Drug Design," <i>Burger's Medicinal Chemistry and Drug Discovery</i> , Fifth Edition, Volume 1, pp. 803-861 (1995).	
		Elliott, et al., "Rational Design of Novel Erythropoiesis Stimulating Protein (ARANESP <sup>®</sup> ): A Super-Sialated Molecule with Increased Biological Activity," <i>Blood</i> , 96: 82a (2000).	
		Garaeu, et al., "Erythropoietin abuse in athletes," <i>Nature</i> , 380: 113 (1996).	
		Maddougall, et al., "Pharmacokinetics of Novel Erythropoiesis Stimulating Protein Compared with Epoetin Alfa in Dialysis Patients," <i>Journal of American Soc. Nephrol.</i> , 10: 2392-2395 (1999).	
		Spivak, et al., "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," <i>Blood</i> , 73(1): 90-99 (1989).	
		Sasaki, et al., "Site-Specific Glycosylation of Human Recombinant Erythropoietin: Analysis of Glycopeptides or Peptides at Each Glycosylation Site by Fast Atom Bombardment Mass Spectrometry," <i>Biochemistry</i> , 27: 8618-8626 (1988).	
		Tsuda, et al., "Comparative Structural Study of N-Linked Oligosaccharides of Urinary and Recombinant Erythropoietins," <i>Biochemistry</i> , 27: 5646-5654 (1988).	
		Davis, et al., "Characterization of Recombinant Human Erythropoietin Produced in Chinese Hamster Ovary Cells," <i>Biochemistry</i> , 26: 2633-2638 (1987).	
		Lasne, et al., "Recombinant erythropoietin in urine," <i>Nature</i> , 405: 635-637 (2000).	
		Syed, et al., "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," <i>Nature</i> , 395: 511-516 (1998).	
		Egrie, et al., "Development and characterization of novel erythropoiesis stimulating protein (NESP)," <i>British Journal of Cancer</i> , 84 (Suppl. 1): 3-10 (2001).	
		Castelli, et al., "Detection of Anti-Erythropoietin Antibodies in Haemodialysis Patients Treated with Recombinant Human Erythropoietin," <i>Pharmacological Research</i> , 41(3): 313-318 (2000).	
		Shadel, et al., "Positive Autoregulation of the <i>Vibrio fischeri luxR</i> Gene," <i>The Journal of Biological Chemistry</i> , 267(11): 7696-7702 (1992).	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

<b>Application Number</b>	10/705,217
<b>Filing Date</b>	07 November 2003
<b>First Named Inventor</b>	Glen A. Evans
<b>Group Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown
<b>Attorney Docket Number</b>	CEN5063 USA CIP

	Narhi, <i>et al.</i> , "The Effect of Carbohydrate on the Structure and Stability of Erythropoietin," <i>The Journal of Biological Chemistry</i> , 266(34): 23022-23026 (1991).	
	Broudy, <i>et al.</i> , "Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide," <i>Proceedings of the National Academy of Science USA</i> , 85: 6513-6517 (1988).	
	Sytkowski, <i>et al.</i> , "Human erythropoietin dimers with markedly enhanced <i>in vivo</i> activity," <i>Proceedings of the National Academy of Science USA</i> , 95: 1184-1188 (1998).	
	Skehel, <i>et al.</i> , "A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody," <i>Proceedings of the National Academy of Science USA</i> , 81: 1779-1783 (1984).	
	Resbeut, <i>et al.</i> , "Carcinoma of the cervix," <i>British Journal of Cancer</i> , 84 (Suppl. 2): 24-30 (2001).	
	Delorme, <i>et al.</i> , "Role of Glycosylation on the Secretion and Biological Activity of Erythropoietin," <i>Biochemistry</i> , 31: 9871-9876 (1992).	
	Elliott, <i>et al.</i> , "Mapping of the Active Site of Recombinant Human Erythropoietin," <i>Blood</i> , 89(2): 493-502 (1997).	
	Takeuchi, <i>et al.</i> , "The Journal of Biological Chemistry", 263(8): 3657-3663 (1988).	
	Fukuda, <i>et al.</i> , "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," <i>Blood</i> , 73(1): 84-89 (1989).	
	Middleton, <i>et al.</i> , "Identification of a Critical Ligand Binding Determinant of the Human Erythropoietin Receptor," <i>The Journal of Biological Chemistry</i> , 271(24): 14045-14054 (1996).	
	Higuchi, <i>et al.</i> , "Role of Sugar Chains in the Expression of the Biological Activity of Human Erythropoietin," <i>The Journal of Biological Chemistry</i> , 267(11): 7703-7709 (1992).	
	Sasaki, <i>et al.</i> , "Carbohydrate Structure of Erythropoietin Expressed in Chinese Hamster Ovary Cells by a Human Erythropoietin cDNA," <i>The Journal of Biological Chemistry</i> , 262(25): 12059-12076 (1987).	
	Endo, <i>et al.</i> , "Heat-Induced Aggregation of Recombinant Erythropoietin in the Intact and Deglycosylated States as Monitored by Gel Permeation Chromatography Combined with a Low-Angle Laser Light Scattering Technique," <i>Journal of Biochemistry</i> , 112: 700-706 (1992).	
	Browne, <i>et al.</i> , "Erythropoietin: Gene Cloning, Protein Structure, and Biological Properties," <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Volume 44: 693-702 (1986).	
	Dordal, <i>et al.</i> , "The Role of Carbohydrate in Erythropoietin Action," <i>Endocrinology</i> , 116: 2292-2299 (1985).	
	Egrie, <i>et al.</i> , "Characterization and biological Effects of Recombinant Human Erythropoietin," <i>Immunobiology</i> , 172: 213-224 (1986).	
	Lukowsky, <i>et al.</i> , "Studies on the Role of Sialic Acid in the Physical and Biological Properties of Erythropoietin," <i>Canadian Journal of Biochemistry</i> , 50: 909-917 (1972).	
	Wen, <i>et al.</i> , "Erythropoietin Structure-Function Relationships," <i>The Journal of Biological Chemistry</i> , 269(36): 22839-22846 (1994).	
	Wen, <i>et al.</i> , "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <i>Blood</i> , 82(5): 1507-1516 (1993).	
	Elliott, <i>et al.</i> , "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," <i>Blood</i> , 87(7): 2702-2713 (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
E:Patent Prosecution\CEN5058 USAD6\PTO1449.doc



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Confirmation Number	
Application Number	10/705,217
Filing Date	07 November 2003
First Named Inventor	Glen A. Evans
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	CEN5063 USA CIP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code <sup>2</sup> (if known)	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
			Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner 's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Copy of PCT International Search Report dated 27 June 2005.	

Examiner Signature	Date Considered
-----------------------	--------------------